In this study, we aimed to assess and compare the real-world PFS and OS outcomes associated with the use of palbociclib and ribociclib in combination with endocrine therapy in patients with HR+, HER2− advanced breast cancer at our cancer center. The gene discussed is ERBB2; the disease is breast carcinoma.